Shares of Bio-Techne Corp. advanced 6.51% to $55.63 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.41% to 6,688.46 and the ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

WASHINGTON (dpa-AFX) - Bio-Techne Corporation's (TECH) activist investor Ananym Capital Management has taken a stake in the company and is urging management to explore strategic alternatives, ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...